Smith & Nephew plc (SNN) Stock Bouncing Back after Dismal Few Years


For most investors, Smith & Nephew plc (NYSE: SNN) is a new name, but it’s been around for a long time. A medical technology company involved in designing and manufacturing medical equipment, Smith and Nephew has an excellent market capitalization of $14.7 billion, while the average trading volume is 823,057 shares. This depicts that in a highly volatile market, SNN has remained a bit stable owing to a huge trading volume. This in turn translates to the domination of bulls for Smith & Nephew during the near future.

Recent Development for SNN

One of the premier products produced by Smith & Nephew was GRAFIX™ Membrane, the human placental tissue product which is used for the treatment of acute and chronic wounds. Recently, SNN has announced that a peer-reviewed study which was published in Advances in Wound Care Journal showed that GRAFIX Cryopreserved Placental Membrane had the ability to cut diabetic foot ulcer recurrence rate in half when compared to the leading cellular and tissue-based product competitors. The findings carry a huge value as diabetic foot ulcer has the capability to affect more than 3 million people annually in the US alone, while the estimated medicare spending for this issue lies between $6 and $18 billion annually.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Valuation Looking Strong

The recent financials and valuation parameters are depicting the signs of recovery Smith & Nephew. The company its business getting slowed down in the wake of the pandemic but is bouncing back steadily. During the third quarter of 2021, SNN generated revenue of $1.26 billion, up 5.5% on a reported basis. For comparison, in the third quarter of 2020 revenue of $1.2 billion was down 3.7% on a reported basis. The dividend yield of 2.2% seems to be okay for the moment, as the company hasn’t raised its dividend since the onset of the pandemic. However, with an increase in earnings, it is expected to do so in the future. The beta value of 0.68 is the epitome of the stability associated with the stock.

Concluding Remarks

Despite all the excellent facts and figures, there appears to be some confusion among the investors regarding investment in SNN, as the stock hasn’t been up to the mark during the last couple of years. However, as recent results have depicted, the stock has the capability to provide prudent investors with hefty returns.


Please enter your comment!
Please enter your name here